Core Viewpoint - Kintor Pharmaceutical-B (2216.HK) experienced a nearly 10% increase in stock price, reaching HKD 2.65, with a total market capitalization of HKD 1.395 billion, following the announcement of its BroncTarget® system entering the special review process by the National Medical Products Administration of China [1][2]. Group 1 - The BroncTarget® system is a breakthrough interventional technology aimed at treating moderate to severe chronic obstructive pulmonary disease (COPD), designed to alleviate symptoms such as cough, sputum production, and breathing difficulties [1]. - The product has received recognition from the regulatory authority for its originality in core technology and significant clinical value [1]. - Confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted across 28 hospitals nationwide [1]. Group 2 - The stock price of Kintor Pharmaceutical-B rose by 9.96%, with a trading volume of 1.271 million shares and a total transaction value of HKD 3.2929 million on January 13 [2]. - The stock reached a high of HKD 2.70 and a low of HKD 2.43 during the trading session, with an average price of HKD 2.59 [2]. - The company has a total share capital of 527 million shares, with a market-to-book ratio of 1.108 [2].

Core Viewpoint - KPB Medical-B (2216.HK) shares rose nearly 10% to HKD 2.65, with a total market capitalization of HKD 1.395 billion, following the announcement that its BroncTarget® lung-targeted radiofrequency ablation system has entered the special review process by the National Medical Products Administration of China, indicating recognition of its original technology and clinical value [1] Company Summary - KPB Medical-B's BroncTarget® system is a breakthrough interventional technology aimed at treating moderate to severe chronic obstructive pulmonary disease (COPD), focusing on alleviating symptoms such as cough, sputum production, and breathing difficulties [1] - The confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted across 28 hospitals nationwide [1] Market Performance - The stock price of KPB Medical-B reached a high of HKD 2.70 and opened at HKD 2.50, with a trading volume of 1.271 million shares [1] - The stock experienced a price fluctuation of 11.20% and has a total share capital of 527 million [1]

Core Viewpoint - KPB Medical-B (02216) has seen a nearly 10% increase in stock price, currently trading at 2.65 HKD, following the announcement of significant regulatory advancements for its medical devices [1] Group 1: Regulatory Approvals - KPB Medical announced that its BroncTarget® lung-targeted radiofrequency ablation system has entered the special review process by the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology and clinical value [1] - The BroncTarget® system is currently undergoing confirmatory clinical trials, with 28 hospitals across the country actively recruiting participants [1] Group 2: Product Launches - The BroncAblate® Smart® lung radiofrequency ablation system has received registration approval from the Hong Kong Department of Health, marking its commercial launch as the world's first natural orifice radiofrequency ablation device for lung cancer [1] - The FleXNeedleCN single-use endoscopic aspiration biopsy needle has also been registered with the Hong Kong Department of Health [1] - The BroncTru® single-use bronchial dilation catheter has successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market [1]

Core Viewpoint - The BroncTarget® lung denervation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its innovative technology and clinical value [1] Group 1: Product Overview - The BroncTarget® system is a targeted lung denervation technology aimed at treating moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1] - It utilizes a bronchoscopic approach to deliver radiofrequency energy precisely to nerve targets, aiming to suppress airway hypercontraction and mucus hypersecretion [1] - The system offers a new treatment option for patients whose symptoms remain poorly controlled despite conventional drug therapy, integrating an "intervention + medication" management strategy [1] Group 2: Technological Features - The BroncTarget® system features innovative designs such as circular multi-electrodes, adjustable orifices, differentiated radiofrequency energy output, real-time temperature and impedance monitoring, and intelligent saline infusion [1] - These features ensure the efficiency and safety of radiofrequency ablation [1] Group 3: Clinical Trials - Confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted simultaneously across 28 hospitals nationwide [2]